Skip to main content
Premium Trial:

Request an Annual Quote

KineMed, Bristol-Myers Squibb Extend Collaboration Covering Alzheimer's Disease

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – KineMed today said that it and Bristol-Myers Squibb have extended a collaboration covering Alzheimer's disease and other neurodegenerative ailments.

Under the extension, KineMed is granting Bristol-Myers Squibb a non-exclusive license to KineMed's technology for the identification and characterization of AD biomarkers in cerebrospinal fluid.

Financial and other terms of the deal were not disclosed.

Based in Emeryville, Calif., KineMed calls itself a "dynamic proteomics" firm, using mass spectrometry to track stable isotopes to measure the rates of change in certain metabolic pathways that may be associated with disease.

"Understanding what is going on in the living brain is key to drug development in neurodegenerative diseases," said David Fineman, president and CEO of KineMed. By measuring fundamental brain process in a living person, "KineMed is enabling research on potential treatments that address the causes, rather than the symptoms of disease," he added.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.